PCSK9 inhibition in the management of familial hypercholesterolemia

•Familial hypercholesterolemia (FH) patients have given some clues to develop new drugs that reduce low-density lipoprotein cholesterol (LDL-C).•Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of LDL receptors.•Loss of PCSK9 in mammals is not considered to influence viabil...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of cardiology 2018-01, Vol.71 (1), p.1-7
1. Verfasser:	Ogura, Masatsune
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anticholesteremic Agents - therapeutic use Familial hypercholesterolemia Humans Hypercholesterolemia - drug therapy Hyperlipoproteinemia Type II - drug therapy Lipoprotein apheresis PCSK9 Proprotein Convertase 9 - antagonists & inhibitors Therapeutic target
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!